OCTAPHARMA
18.2.2021 10:45:06 CET | Business Wire | Press release
Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq® ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623 ).
The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq® . The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single product in true PUPs.
Of 105 evaluable PUPs with severe haemophilia A who received Nuwiq® for the prevention and treatment of bleeding:
- 16.2% (17/105) of patients developed high-titre inhibitors
- 10.5% (11/105) of patients developed low-titre inhibitors, five of which were transient
- 26.7% (28/105) of patients developed any inhibitor
“The NuProtect study showed that there was a low risk of inhibitor development in PUPs starting treatment with Nuwiq® ,” commented Dr Ri Liesner, coordinating investigator of the NuProtect study and clinician at Great Ormond Street Hospital for Children in London, UK. “These data indicate Nuwiq® may be an attractive option for people newly diagnosed with severe haemophilia A, who are young children and represent a vulnerable patient subset .”
The development of inhibitors to replacement factor VIII (FVIII) is a concern for doctors, as well as for patients and their families, particularly when first starting treatment. Inhibitors render FVIII therapy ineffective and limit treatment options.
These data complement the wealth of clinical experience in patients with haemophilia A receiving Nuwiq® for the treatment and prevention of bleeding.
“Nuwiq® was developed in a human cell line with the aim of minimising inhibitor risk in PUPs,” said Larisa Belyanskaya, Head of Octapharma’s IBU Haematology. “We are pleased to be able to share these positive data, which reflect this aim and which we hope will contribute to addressing this key treatment challenge.”
“We know that haemophilia A patients face a lifetime of treatment decisions ,” commented Olaf Walter, Board Member at Octapharma. “These data highlight the potential of Nuwiq® to reassure PUPs and their families as they start their treatment. This publication brings us closer to Octapharma’s goal of enabling all patients to lead healthy lives .”
Earlier this year the FDA approved the inclusion of the immunogenicity data from the NuProtect study in the Nuwiq® Prescribing Information. Further publications on other analyses from the NuProtect study are planned.
Professor Anthony Chan, a co-author of the publication and Professor of Paediatrics at McMaster University, Canada, said: “Congratulations and thanks to Octapharma for developing Nuwiq, sponsoring the trial and providing a very good therapy for patients with haemophilia A. ”
Octapharma would also like to extend thanks to all participating centres, as well as patients and their caregivers, for their contribution to the study.
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1 . It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1 . Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1 . Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2 . Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2 .
1. Lissitchkov T et al. Ther Adv Hematol
2019; 10:2040620719858471.
2. Nuwiq®
Summary of Product Characteristics.
About Haemophilia A
Haemophilia A is an X-linked hereditary bleeding disorder caused by a deficiency of factor VIII (FVIII) which, if left untreated, may lead to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. The disorder affects around one in every 10,000 males worldwide. Prophylaxis with replacement FVIII therapy reduces the number of bleeding episodes and the risk of permanent joint damage.
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Octapharma employs more than 9,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, and operates more than 160 plasma donation centres across Europe and the USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005452/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
